Bolt Biotherapeutics develops immuno-oncology therapeutics using its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which combines tumor-targeting antibodies with immune-stimulating payloads to activate a patient's innate immune system against cancer. The company's lead program, BDC-4182, targets claudin 18.2 in gastric and related cancers and is in clinical development; the company also maintains pipeline programs targeting CEA, PD-L1, and dectin-2, some currently on hold. Bolt generates revenue through milestone payments and royalties from partnerships with pharmaceutical companies including Genmab, Innovent Biologics, and Toray Industries, as well as licensing arrangements with research institutions, while outsourcing all manufacturing to contract partners.